ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs' Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive solid
ITM to supply Advanced Accelerator Applications on an industrial scale with its high-quality n.c.a. lutetium-177 as core component of the newly approved radiotherapeutic, PluvictoTM ITM Isotope
ICIF and Portland Holdings add to recently secured EUR 25 million equity investment from Grand Pharma, bringing the total in this financing round to EUR 58 million ITM Isotope Technologies Munich
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will support an industry-sponsored satellite symposium titled, "Multi-disciplinary Approach